Sign In
Sign In
The majority of oncology drugs (70 percent) will be high-cost orphan drugs–focused on relatively small group of patients with rare subsets of cancer. (Photo: Shutterstock)Recommended Stories
Mammograms at 40? New breast cancer screening guidelines spark fresh debate
While physicians mostly applauded the Preventive Services Task Force’s recommendation that women get routine breast cancer screenings starting at 40, down from 50, some doctors and researchers disagree with the data used.
Ford sues Blue Cross, accusing insurer of price fixing that led to ‘astronomical profits’
Ford Motor Co., which paid $500 million in premiums to BCBS, alleges it was "overcharged" for health insurance in a new lawsuit that's related to the $2.7 billion antitrust settlement that BCBS and member companies reached in 2020.
Senate votes to undo Biden’s $10,000 student loan debt forgiveness plan
The Senate has voted to repeal Biden’s student debt relief plan, although the president has said he will veto the legislation if it reaches his desk. If so, the Supreme Court will have the final decision this month.
Resource Center
eBook
Sponsored by Grail
Closing The Cancer Gap: Health Inequities And How Employers Can Help
Cancer prevention, diagnosis, and treatment outcomes remain stubbornly dire for underserved and hard-to-reach populations. But employers are in a powerful position to address the health inequities and social determinants that shape those statistics. Download this eBook to learn strategies to affect meaningful change in employee health.
Infographic
Sponsored by ArmadaCare
Plan changes are inevitable. And changes can often lead to unhappy clients. Download this infographic and learn how to mitigate those unwanted changes now without breaking the bank.
White Paper
Sponsored by Peppy Health Corporation
6 Steps to Support Colleagues Going Through Menopause
Download this white paper and learn about a high-impact tool to improve your employees’ health and well-being; helping your organization become a destination employer.
BenefitsPRO
Don’t miss crucial news and insights you need to navigate the shifting employee benefits industry. Join BenefitsPRO.com now!
- Unlimited access to BenefitsPRO.com - your roadmap to thriving in a disrupted environment
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
- Exclusive discounts on BenefitsPRO.com and ALM events.
Copyright © 2023 ALM Global, LLC. All Rights Reserved.